U.S. Senate Reaches Agreement to Cap Insulin Costs at $35, Semafor Reports

The U.S. Senate has reached an agreement to cap insulin costs at $35, according to Semafor. This move aims to make insulin more affordable for Americans who rely on the medication for managing diabetes. The decision comes amid ongoing discussions about healthcare costs and accessibility in the United States. The cap is expected to provide significant financial relief to patients who have been burdened by high insulin prices. This agreement marks a step forward in addressing the broader issue of rising healthcare expenses in the country.